Search details
1.
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Future Oncol
; 15(12): 1363-1383, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30758227
2.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 16(7): 763-74, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-26045340
3.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Lancet Oncol
; 16(3): 328-37, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25701171
4.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(1): 59-68, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24331154
5.
Lung cancer after treatment for breast cancer.
Lancet Oncol
; 11(12): 1184-92, 2010 Dec.
Article
in English
| MEDLINE | ID: mdl-20541465
6.
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Lancet Oncol
; 11(8): 733-40, 2010 Aug.
Article
in English
| MEDLINE | ID: mdl-20650686
7.
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Lung Cancer
; 64(1): 60-5, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-18692272
8.
Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Immunotherapy
; 11(15): 1337-1351, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31556762
9.
Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment.
Clin Lung Cancer
; 9(2): 92-101, 2008 Mar.
Article
in English
| MEDLINE | ID: mdl-18501095
10.
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 19(2): 130-138.e2, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29158123
11.
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
J Thorac Oncol
; 13(2): 228-236, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29158193
12.
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.
Thromb Res
; 167: 50-56, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29787943
13.
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
JAMA Oncol
; 4(12): e183486, 2018 12 01.
Article
in English
| MEDLINE | ID: mdl-30177994
14.
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
J Thorac Oncol
; 13(2): 165-183, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29175116
15.
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
Clin Lung Cancer
; 19(4): 331-339, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29773328
16.
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Crit Rev Oncol Hematol
; 63(1): 53-64, 2007 Jul.
Article
in English
| MEDLINE | ID: mdl-17368037
17.
Modern management of small-cell lung cancer.
Drugs
; 67(15): 2135-52, 2007.
Article
in English
| MEDLINE | ID: mdl-17927281
18.
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Clin Cancer Res
; 12(20 Pt 1): 6049-55, 2006 Oct 15.
Article
in English
| MEDLINE | ID: mdl-17062680
19.
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Lancet
; 366(9496): 1527-37, 2005.
Article
in English
| MEDLINE | ID: mdl-16257339
20.
Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?
Drugs
; 66(15): 1919-31, 2006.
Article
in English
| MEDLINE | ID: mdl-17100404